Skip to main content Skip to search Skip to main navigation

EMA: Concept Paper on the Revision of GMP Guide Part IV on ATMPs

EMA has published a concept paper on the revision of GMP Guide Part IV on ATMPs for public consultation. 

The proposed revision will embrace the use of new technologies that are not currently covered in the current version (e.g. automated advanced technology, (closed) single use systems, fast rapid microbiological testing methods).

Following the publication of a new regulation on standards of quality and safety for substances of human origin intended for human application there is also a need to update legal references and definitions for the starting material of human origin.

Since the introduction of the revised GMP Annex I for the manufacture of sterile products has modified and clarified some requirements compared to the current ATMP guideline, the proposed revision of the ATMP guideline is to align with the current Annex 1 while maintaining a flexible approach for the production of ATMPs.

It is noted that the current revision will only focus on the sterile manufacture sections related to the updated version of the Annex 1 and not to update any other topics/sections outside of that scope.

The consultation closes on 8 July 2025.


Source:

EMA: GMP/GDP Inspectors Working Group (GMP/GDP IWG) Concept paper on the revision of Part IV Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

The ABC of User Requirements Specification (URS)

The ABC of User Requirements Specification (URS)

In the URS, the future user defines what the system should be capable of, but also what it is limited to. In addition to the (testable!) technical requirements, regulatory require-ments should also be taken into account.
Read more
What is the Importance of Data Integrity?

What is the Importance of Data Integrity?

Here's the answer:
Read more
EDQM: Updated Guideline on CEP Revisions and Renewals

EDQM: Updated Guideline on CEP Revisions and Renewals

The European Directorate for the Quality of Medicines & HealthCare has published a revised version of its guideline on the revision and renewal of Certificates of Suitability (CEPs) (PA/PH/CEP (04) 02), aligning it with recent EU legislation on variation procedures.
Read more
EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

The European Medicines Agency (EMA) has published revised annexes to the ICH Q3C guideline (“Impurities: Guideline for Residual Solvents”) and the corresponding veterinary guideline VICH GL18 for public consultation. The commenting period is open until the end of June 2026.
Read more
FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Previous
Next